Lotus Eye Hospital and Institute cash flow

Latest FY26

Cash from operations: ₹3.1cr−36.6% on FY25
Capital spending: ₹13.0cr+170.2% on FY25
Free cash flow: −₹9.9cr₹0.1 cr in FY25
Cash from financing: ₹9.0cr−₹1.6 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	3.7	3.0	3.7	3.0
	—	0.9	0.4	0.1	0.1
	—	−0.2	−0.4	−0.5	−0.5
	—	−0.5	−0.4	−0.4	−0.4
	—	0.0	−0.0	−0.0	0.0
	—	−0.0	−0.6	−0.4	−0.5
	—	0.1	−0.1	−0.1	−0.5
	—	−0.2	−0.0	0.0	0.0
	—	−0.2	0.2	−0.2	−1.2
	—	−0.8	0.0	−0.6	1.2
	—	0.1	2.2	0.0	0.0
	—	−0.1	−0.1	0.3	−0.4
	—	0.0	−0.1	0.1	0.0
	—	0.7	0.2	0.0	0.0
	—	−0.0	0.0	0.0	0.0
	—	−0.0	−0.1	0.8	−0.1
	—	0.0	0.0	−0.0	0.0
	—	−0.0	−0.1	0.0	0.0
	—	0.0	0.0	−0.1	−0.4
Cash from operating activities
	0.2	−0.1	1.4	4.0	5.7
	—	3.5	4.2	2.7	0.1
	—	3.4	5.6	6.7	5.8
	—	0.3	0.6	1.0	1.4
	—	3.1	4.9	5.7	4.4
Cash from investing activities
	—	13.0	4.8	5.6	3.1
	—	0.0	0.0	0.1	0.0
	—	0.2	0.4	0.5	0.5
	—	0.5	0.4	0.4	0.4
	—	−12.4	−4.0	−4.6	−2.2
Cash from financing activities
	—	15.0	0.0	0.0	0.0
	—	3.6	0.0	0.0	0.0
	—	1.6	1.2	2.3	0.4
	—	—	—	0.0	0.1
	—	0.8	0.4	0.1	0.1
	—	0.0	0.0	1.0	1.0
	—	9.0	−1.6	−3.4	−1.7
	—	−0.2	−0.6	−2.4	0.5
	—	−0.2	−0.6	−2.4	0.5
	—	—	—	6.9	9.3
Reference items
	4.9	3.4	3.4	6.5	7.6
	8.5%	6.3%	6.9%	13.6%	16.1%
	−9.9	−9.9	0.1	0.0	1.3
	—	0.7	−0.2	−0.1	—
	−₹4.76	−₹4.76	₹0.06	₹0.02	₹0.62
	—	39.03×	6.69×	1.95×	1.08×
	—	0.3	0.6	1.0	1.4
	—	0.8	0.4	0.1	0.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LOTUSEYE₹110.00

Lotus Eye Hospital and Institute Limited

· Pharma & Health

₹ CrorePeersGPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMED DRAGARWQ KMCSHIL KOVAIMcap ₹229 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	3.0	3.7	3.0	3.7	—
+ Finance Costs	0.1	0.1	0.4	0.9	—
+ Interest Income	-0.5	-0.5	-0.4	-0.2	—
+ Other — Cash Effects are Investing / Financing	-0.4	-0.4	-0.4	-0.5	—
+ Other Reconciling Items	0.0	-0.0	-0.0	0.0	—
Changes in Working Capital
+ Inventories	-0.5	-0.4	-0.6	-0.0	—
+ Trade Receivables — Current	-0.5	-0.1	-0.1	0.1	—
+ Other Financial Assets — Non-current	0.0	0.0	-0.0	-0.2	—
+ Other Current Assets	-1.2	-0.2	0.2	-0.2	—
+ Other Non-current Assets	1.2	-0.6	0.0	-0.8	—
+ Other Bank Balances	0.0	0.0	2.2	0.1	—
+ Trade Payables — Current	-0.4	0.3	-0.1	-0.1	—
+ Trade Payables — Non-current	0.0	0.1	-0.1	0.0	—
+ Other Financial Liabilities — Current	0.0	0.0	0.2	0.7	—
+ Other Financial Liabilities — Non-current	0.0	0.0	0.0	-0.0	—
+ Other Current Liabilities	-0.1	0.8	-0.1	-0.0	—
+ Other Non-current Liabilities	0.0	-0.0	0.0	0.0	—
+ Provisions — Current	0.0	0.0	-0.1	-0.0	—
+ Provisions — Non-current	-0.4	-0.1	0.0	0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	5.7	4.0	1.4	-0.1	0.2
+ Total Adjustments (incl. Working Capital)	0.1	2.7	4.2	3.5	—
Cash from Operations (pre-tax)	5.8	6.7	5.6	3.4	—
+ Income Taxes Paid	1.4	1.0	0.6	0.3	—
Cash from Operating Activities	4.4	5.7	4.9	3.1	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	3.1	5.6	4.8	13.0	—
+ Disp of Fixed Assets	0.0	0.1	0.0	0.0	—
+ Interest Received — Investing	0.5	0.5	0.4	0.2	—
+ Other Inflows / (Outflows) — Investing	0.4	0.4	0.4	0.5	—
Cash from Investing Activities	-2.2	-4.6	-4.0	-12.4	—
Cash from Financing Activities
+ Proceeds from Borrowings	0.0	0.0	0.0	15.0	—
+ Repayment of Borrowings	0.0	0.0	0.0	3.6	—
+ Payment of Lease Liabilities	0.4	2.3	1.2	1.6	—
+ Payment of Finance Lease Liabilities	0.1	0.0	—	—	—
+ Interest Paid	0.1	0.1	0.4	0.8	—
+ Dividends Paid	1.0	1.0	0.0	0.0	—
Cash from Financing Activities	-1.7	-3.4	-1.6	9.0	—
Net Changes in Cash (pre-FX)	0.5	-2.4	-0.6	-0.2	—
Net Changes in Cash	0.5	-2.4	-0.6	-0.2	—
Closing Cash	9.3	6.9	—	—	—
Reference Items
EBITDA	7.6	6.5	3.4	3.4	4.9
EBITDA Margin %	16.13	13.55	6.93	6.30	8.47
Free Cash Flow (CFO − Capex)	1.3	0.0	0.1	-9.9	-9.9
Free Cash Flow to Equity	—	-0.1	-0.2	0.7	—
Free Cash Flow per Basic Share	0.62	0.02	0.06	-4.76	-4.76
Cash Flow to Net Income	1.08	1.95	6.69	39.03	—
Cash Paid for Taxes	1.4	1.0	0.6	0.3	—
Cash Paid for Interest	0.1	0.1	0.4	0.8	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.